tbuckley/cabot-search huggingface dataset:
Wastewater Surveillance for Influenza A Virus and H5 Subtype Concurrent with the Highly Pathogenic Avian Influenza A(H5N1) Virus Outbreak in Cattle and Poultry and Associated Human Cases — United States, May 12–July 13, 2024
Authors: Souci Louis, Miguella Mark-Carew, Matthew Biggerstaff, Jonathan Yoder, Alexandria B. Boehm, Marlene K. Wolfe, Matthew Flood, Susan Peters, Mary Grace Stobierski, Joseph Coyle, Matthew T. Leslie, Mallory Sinner, Dawn Nims, Victoria Salinas, Layla Lustri, Heidi Bojes, Varun Shetty, Elisabeth Burnor, Angela Rabe, Guinevere Ellison-Giles, Alexander T. Yu, Austin Bell, Stephanie Meyer, Ruth Lynfield, Melissa Sutton, Ryan Scholz, Rebecca Falender, Shannon Matzinger, Allison Wheeler, Farah S. Ahmed, John Anderson, Kate Harris, Austin Walkins, Surabhi Bohra, Victoria O’Dell, Virginia T. Guidry, Ariel Christensen, Zack Moore, Erica Wilson, Joshua L. Clayton, Hannah Parsons, Krista Kniss, Alicia Budd, Jeffrey W. Mercante, Heather E. Reese, Michael Welton, Megan Bias, Jenna Webb, Daniel Cornforth, Scott Santibañez, Rieza H. Soelaeman, Manpreet Kaur, Amy E. Kirby, John R. Barnes, Nicole Fehrenbach, Sonja J. Olsen, Margaret A. Honein
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

As part of the response to the highly pathogenic avian influenza A(H5N1) virus outbreak in U.S. cattle and poultry and the associated human cases, CDC and partners are monitoring influenza A virus levels and detection of the H5 subtype in wastewater. Among 48 states and the District of Columbia that performed influenza A testing of wastewater during May 12-July 13, 2024, a weekly average of 309 sites in 38 states had sufficient data for analysis, and 11 sites in four states reported high levels of influenza A virus. H5 subtype testing was conducted at 203 sites in 41 states, with H5 detections at 24 sites in nine states. For each detection or high level, CDC and state and local health departments evaluated data from other influenza surveillance systems and partnered with wastewater utilities and agriculture departments to investigate potential sources. Among the four states with high influenza A virus levels detected in wastewater, three states had corresponding evidence of human influenza activity from other influenza surveillance systems. Among the 24 sites with H5 detections, 15 identified animal sources within the sewershed or adjacent county, including eight milk-processing inputs. Data from these early investigations can help health officials optimize the use of wastewater surveillance during the upcoming respiratory illness season.
SMARCA5-mediated chromatin remodeling is required for germinal center formation
Authors: Liat Stoler-Barak, Dominik Schmiedel, Avital Sarusi-Portuguez, Adi Rogel, Ronnie Blecher-Gonen, Zhana Haimon, Tomas Stopka, Ziv Shulman
Journal: The Journal of Experimental Medicine (2024)

The establishment of long-lasting immunity against pathogens is facilitated by the germinal center (GC) reaction, during which B cells increase their antibody affinity and differentiate into antibody-secreting cells (ASC) and memory cells. These events involve modifications in chromatin packaging that orchestrate the profound restructuring of gene expression networks that determine cell fate. While several chromatin remodelers were implicated in lymphocyte functions, less is known about SMARCA5. Here, using ribosomal pull-down for analyzing translated genes in GC B cells, coupled with functional experiments in mice, we identified SMARCA5 as a key chromatin remodeler in B cells. While the naive B cell compartment remained unaffected following conditional depletion of Smarca5, effective proliferation during B cell activation, immunoglobulin class switching, and as a result GC formation and ASC differentiation were impaired. Single-cell multiomic sequencing analyses revealed that SMARCA5 is crucial for facilitating the transcriptional modifications and genomic accessibility of genes that support B cell activation and differentiation. These findings offer novel insights into the functions of SMARCA5, which can be targeted in various human pathologies.
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer
Authors: Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S. Ramalingam, Shi-Yong Sun
Journal: The Journal of Experimental Medicine (2024)

The inevitable acquired resistance to osimertinib (AZD9291), an FDA-approved third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR activating or T790M resistant mutations, limits its long-term clinical benefit. Telomere maintenance via telomerase reactivation is linked to uncontrolled cell growth and is a cancer hallmark and an attractive cancer therapeutic target. Our effort toward understanding the action mechanisms, including resistance mechanisms, of osimertinib has led to the identification of a novel and critical role in maintaining c-Myc–dependent downregulation of hTERT, a catalytic subunit of telomerase, and subsequent inhibition of telomerase/telomere and induction of telomere dysfunction in mediating therapeutic efficacy of osimertinib. Consequently, osimertinib combined with the telomere inhibitor, 6-Thio-dG, which is currently tested in a phase II trial, effectively inhibited the growth of osimertinib-resistant tumors, regressed EGFRm NSCLC patient-derived xenografts, and delayed the emergence of acquired resistance to osimertinib, warranting clinical validation of this strategy to manage osimertinib acquired resistance.
Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases
Authors: Praveen Krishna Veerasubramanian, Thomas A. Wynn, Jie Quan, Fridrik J. Karlsson
Journal: The Journal of Experimental Medicine (2024)

Dysregulated signaling from TNF and TNFR proteins is implicated in several immune-mediated inflammatory diseases (IMIDs). This review centers around seven IMIDs (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, and asthma) with substantial unmet medical needs and sheds light on the signaling mechanisms, disease relevance, and evolving drug development activities for five TNF/TNFR signaling axes that garner substantial drug development interest in these focus conditions. The review also explores the current landscape of therapeutics, emphasizing the limitations of the approved biologics, and the opportunities presented by small-molecule inhibitors and combination antagonists of TNF/TNFR signaling.
Interleukin-33–activated basophils promote asthma by regulating Th2 cell entry into lung tissue
Authors: Martijn J. Schuijs, Claudia M. Brenis Gomez, Fabian Bick, Justine Van Moorleghem, Manon Vanheerswynghels, Geert van Loo, Rudi Beyaert, David Voehringer, Richard M. Locksley, Hamida Hammad, Bart N. Lambrecht
Journal: The Journal of Experimental Medicine (2024)

Asthma is characterized by lung eosinophilia, remodeling, and mucus plugging, controlled by adaptive Th2 effector cells secreting IL-4, IL-5, and IL-13. Inhaled house dust mite (HDM) causes the release of barrier epithelial cytokines that activate various innate immune cells like DCs and basophils that can promote Th2 adaptive immunity directly or indirectly. Here, we show that basophils play a crucial role in the development of type 2 immunity and eosinophilic inflammation, mucus production, and bronchial hyperreactivity in response to HDM inhalation in C57Bl/6 mice. Interestingly, conditional depletion of basophils during sensitization did not reduce Th2 priming or asthma inception, whereas depletion during allergen challenge did. During the challenge of sensitized mice, basophil-intrinsic IL-33/ST2 signaling, and not FcεRI engagement, promoted basophil IL-4 production and subsequent Th2 cell recruitment to the lungs via vascular integrin expression. Basophil-intrinsic loss of the ubiquitin modifying molecule Tnfaip3, involved in dampening IL-33 signaling, enhanced key asthma features. Thus, IL-33-activated basophils are gatekeepers that boost allergic airway inflammation by controlling Th2 tissue entry.
Recruitment of the m6A/m6Am demethylase FTO to target RNAs by the telomeric zinc finger protein ZBTB48
Authors: Syed Nabeel-Shah, Shuye Pu, Giovanni L Burke, Nujhat Ahmed, Ulrich Braunschweig, Shaghayegh Farhangmehr, Hyunmin Lee, Mingkun Wu, Zuyao Ni, Hua Tang, Guoqing Zhong, Edyta Marcon, Zhaolei Zhang, Benjamin J Blencowe, Jack F Greenblatt
Journal: Genome biology (2024)
<i>Notes from the Field:</i> Support for Wastewater Monitoring and Influence on Protective Behavioral Intentions Among Adults — United States, July 2024
Authors: Rieza H. Soelaeman, Danielle Kleven, Jena Losch, Michael Vega, S. Nicole Fehrenbach, Jessica N. Ricaldi, Diana Valencia, Scott Santibañez
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

In 2020, during the COVID-19 pandemic, CDC established the National Wastewater Surveillance System and later expanded it to include mpox and influenza A data dashboards.
Discovery of cGAS as a DNA-Sensing Enzyme That Triggers Inflammation
Authors: Zhijian J. Chen
Journal: JAMA (2024)

In this Viewpoint, 2024 Albert Lasker Basic Medical Research Award winner Zhijian J. Chen describes his discovery of cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS), a DNA-sensing enzyme that triggers inflammation.
Corrigendum to “PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease” [Metabolism Volume 150, January 2024, 155736, PMID: 7967646]
Authors: Vatsal Sachan, Maïlys LeDévéhat, Anna Roubtsova, Rachid Essalmani, Jean-Francois Laurendeau, Damien Garçon, Delia Susan-Sesiga, Stéphanie Duval, Sahar Mikaeeli, Josée Hamelin, Alexandra Evagelidis, Michael Chong, Guillaume Paré, Elizabeta Chernetsova, Zu-Hua Gao, Isabelle Robillard, Matthieu Ruiz, Vincent Quoc-Huy Trinh, Jennifer L Estall, May Faraj, Richard C Austin, Martin Sauvageau, Annik Prat, Robert S Kiss, Nabil G Seidah
Journal: Metabolism (2024)
Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories
Authors: Moez Karim Aziz, Donald Molony, Dominique Monlezun, Travis Holder, Oliver Brunckhorst, Noel Higgason, Jerry Roland, Resa Magill, Mariya Fatakdawala, Alexander Iacobucci, Neal Mody-Bailey, Chris Owen, Andrew Zarker, Emma Thames, Justin Swaby, Daniel Xiao, Lily Choi, Shubh Desai, Jacob Galan, Brett Deng, Taylor Hartshorne, Alexis Nichols, Allan Zhang, Jared Imber, Jeffrey Song, William Jones, Alexis Rivas, Darren Sanchez, Maya Guhan, Giorgio Gandaglia, Shreyas Ranganath, Jerril Jacob, Skyler Howell, Juan Plana, Roderick van den Bergh, Matthew Roberts, Silke Gillessen Sommer, Jan Oldenburg, Guillaume Ploussard, Derya Tilki, Ivo Schoots, Erik Briers, Johan Stranne, Olivier Rouviere, Inge van Oort, Daniela Oprea-Lager, Maria De Santis, Philip Cornford, Efstratios Koutroumpakis, Ali Ziaolhagh, Abdelrahman Ali, Syed Wamique Yusuf, Cezar Iliescu, Steven Canfield
Journal: European Urology (2024)
Single‐cell transcriptomic atlas reveals immune and metabolism perturbation of depression in the pathogenesis of breast cancer
Authors: Lingling Wu, Junwei Liu, Yimeng Geng, Jianwen Fang, Xingle Gao, Jianbo Lai, Minya Yao, Shaojia Lu, Weiwei Yin, Peifen Fu, Wei Chen, Shaohua Hu
Journal: Cancer Communications (2024)
Differential diagnosis of suspected multiple sclerosis: global health considerations
Authors: Jorge Correale, Andrew J Solomon, Jeffrey A Cohen, Brenda L Banwell, Fernando Gracia, Tirisham V Gyang, Fernando Hamuy Diaz de Bedoya, Mary P Harnegie, Bernhard Hemmer, Anu Jacob, Ho Jin Kim, Ruth Ann Marrie, Farrah J Mateen, Scott D Newsome, Lekha Pandit, Naraporn Prayoonwiwat, Mohammad A Sahraian, Douglas K Sato, Deanna Saylor, Fu-Dong Shi, Aksel Siva, Kevin Tan, Shanthi Viswanathan, Mike P Wattjes, Brian Weinshenker, Bassem Yamout, Kazuo Fujihara
Journal: The Lancet Neurology (2024)
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
Authors: Jeffrey A Allen, Jie Lin, Ivana Basta, Tina Dysgaard, Christian Eggers, Jeffrey T Guptill, Kelly G Gwathmey, Channa Hewamadduma, Erik Hofman, Yessar M Hussain, Satoshi Kuwabara, Gwendal Le Masson, Frank Leypoldt, Ting Chang, Marta Lipowska, Murray Lowe, Giuseppe Lauria, Luis Querol, Mihaela-Adriana Simu, Niraja Suresh, Anissa Tse, Peter Ulrichts, Benjamin Van Hoorick, Ryo Yamasaki, Richard A Lewis, Pieter A van Doorn
Journal: The Lancet Neurology (2024)
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy
Authors: Christopher R S Belder, Delphine Boche, James A R Nicoll, Zane Jaunmuktane, Henrik Zetterberg, Jonathan M Schott, Frederik Barkhof, Nick C Fox
Journal: The Lancet Neurology (2024)
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial
Authors: Vinojini Vivekanandam, Iwona Skorupinska, Dipa L Jayaseelan, Emma Matthews, Richard J Barohn, Michael P McDermott, Michael G Hanna
Journal: The Lancet Neurology (2024)
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia
Authors: Lilyana Amezcua, Dalia Rotstein, Afsaneh Shirani, Olga Ciccarelli, Daniel Ontaneda, Melinda Magyari, Victor Rivera, Dorlan Kimbrough, Ruth Dobson, Bruce Taylor, Mitzi Williams, Ruth Ann Marrie, Brenda Banwell, Bernhard Hemmer, Scott D Newsome, Jeffrey A Cohen, Andrew J Solomon, Walter Royal
Journal: The Lancet Neurology (2024)
Retraction notice to “Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes” [Biomaterials 34/1 (2013) 14383]
Authors: Lei Wang, Jinjin Shi, Hongling Zhang, Haixia Li, Yan Gao, Zhenzhen Wang, Honghong Wang, Lulu Li, Chaofeng Zhang, Chengqun Chen, Zhenzhong Zhang, Yun Zhang
Journal: Biomaterials (2024)
Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post-hoc analysis of the PREDESCI trial
Authors: Elton Dajti, Càndid Villanueva, Annalisa Berzigotti, Anna Brujats, Agustín Albillos, Joan Genescà, Juan C Garcia-Pagán, Antonio Colecchia, Jaume Bosch
Journal: Journal of Hepatology (2024)
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma
Authors: Jie Jin, Hong Cen, Keshu Zhou, Xiaohong Xu, Fei Li, Tao Wu, Haiyan Yang, Zhen Wang, Zhiming Li, Wenyang Huang, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Clinical Cancer Research (2024)

Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- and T-cell lymphomas, but as a drug class, these agents have frequently been observed to have tolerability limitations. Next-generation agents that improve the tolerability while maintaining efficacy are desirable.
Considerations for future trials in cerebral cavernous malformations – Authors' reply
Authors: Rustam Al-Shahi Salman, Laura Forsyth, Steff C Lewis, James J M Loan, Aileen R Neilson, Jacqueline Stephen, Neil Kitchen, Kirsty A Harkness, Peter J A Hutchinson, Conor Mallucci, Julia Wade, Philip M White
Journal: The Lancet Neurology (2024)
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Authors: Courtney D DiNardo, Divij Verma, Natalia Baran, Tushar D Bhagat, Anna Skwarska, Alessia Lodi, Kapil Saxena, Tianyu Cai, Xiaoping Su, Veronica A Guerra, Gowri Poigaialwar, Vinitha M Kuruvilla, Sergej Konoplev, Shanisha Gordon-Mitchell, Kith Pradhan, Srinivas Aluri, G Lavender Hackman, Sovira Chaudhry, Meghan Collins, Shannon R Sweeney, Jonathan Busquets, Atul Singh Rathore, Qing Deng, Michael R Green, Steven Grant, Susan Demo, Gaurav S Choudhary, Srabani Sahu, Beamon Agarwal, Mason Spodek, Victor Thiruthuvanathan, Britta Will, Ulrich Steidl, George D Tippett, Jan Burger, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Tapan Kadia, Steven Kornblau, Naval G Daver, Kiran Naqvi, Nicholas J Short, Guillermo Garcia-Manero, Stefano Tiziani, Amit Verma, Marina Konopleva
Journal: Nature Cancer (2024)
Echocardiographic screening for heart failure and optimization of the care pathway for individuals with pacemakers: a randomized controlled trial
Authors: Maria F Paton, John Gierula, Haqeel A Jamil, Sam Straw, Judith E Lowry, Rowena Byrom, Thomas A Slater, Alasdair M Fellows, Richard G Gillott, Hemant Chumun, Paul Smith, Richard M Cubbon, Deborah D Stocken, Mark T Kearney, Klaus K Witte
Journal: Nature Medicine (2024)
A comprehensive review on the development of chiral Cu, Ni, and Zn complexes as pharmaceutical agents over the past decades: Synthesis, molecular structure and biological activity
Authors: Zahra Kazemi, Nakisa Moini, Hadi Amiri Rudbari, Nicola Micale
Journal: Medicinal Research Reviews (2024)

Abstract Chirality is a fundamental and widespread geometric structural property in living organisms that most biomacromolecules including nucleic acids, proteins and enzymes, possess. Consequently, the development of chiral drugs capable of binding specific targets have gradually gained wide attention in recent decades due to their selective effects on a broad spectrum of biological events ranging from cell metabolism to cell fate. In this context, the synthesis of chiral compounds as promising therapeutic candidates has assumed a major role in drug discovery. Among them, chiral metal complexes have attracted considerable interest due to their unique and intriguing structural features that could enable overcoming side effects and drug‐resistance phenomena of metal − based drugs currently in the market such as cisplatin. In the current scenario, an in‐depth overview of non‐platinum chiral complexes needs to be presented and carried forward. Therefore, in this perspective article, an update of the scientific development of bioactive chiral copper, zinc and nickel complexes have been reported since they have not been thoroughly reviewed so far. Specifically, we focused the article mainly on metal complexes containing chiral ligands (type 2 chirality) as in literature they are more numerous than those with chirality at the metal center (type 1 chirality). Herein, not only their biological activity but also their mechanism of action is summarized. Furthermore, in the final section of the article we have highlighted copper‐based complexes as those with a superior biological activity profile and greater prospects for development as a drug.
Management of Patients With Cardiac Arrest Requiring Interfacility Transport: A Scientific Statement From the American Heart Association
Authors: Teresa L. May, Erin A. Bressler, Rebecca E. Cash, Francis X. Guyette, Steve Lin, Nicholas A. Morris, Ashish R. Panchal, Stacy M. Perrin, Melissa Vogelsong, Joyce Yeung, Jonathan Elmer
Journal: Circulation (2024)

People who experience out-of-hospital cardiac arrest often require care at a regional center for continued treatment after resuscitation, but many do not initially present to the hospital where they will be admitted. For patients who require interfacility transport after cardiac arrest, the decision to transfer between centers is complex and often based on individual clinical characteristics, resources at the presenting hospital, and available transport resources. Once the decision has been made to transfer a patient after cardiac arrest, there is little direct guidance on how best to provide interfacility transport. Accepting centers depend on transferring emergency departments and emergency medical services professionals to make important and nuanced decisions about postresuscitation care that may determine the efficacy of future treatments. The consequences of early care are greater when transport delays occur, which is common in rural areas or due to inclement weather. Challenges of providing interfacility transfer services for patients who have experienced cardiac arrest include varying expertise of clinicians, differing resources available to them, and nonstandardized communication between transferring and receiving centers. Although many aspects of care are insufficiently studied to determine implications for specific out-of-hospital treatment on outcomes, a general approach of maintaining otherwise recommended postresuscitation care during interfacility transfer is reasonable. This includes close attention to airway, vascular access, ventilator management, sedation, cardiopulmonary monitoring, antiarrhythmic treatments, blood pressure control, temperature control, and metabolic management. Patient stability for transfer, equity and inclusion, and communication also must be considered. Many of these aspects can be delivered by protocol-driven care.
Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells
Authors: Shuai Wang, Lijun Meng, Nan Xu, Huan Chen, Zhaofeng Xiao, Di Lu, Xiaohui Fan, Limin Xia, Jun Chen, Shusen Zheng, Qiang Wei, Xuyong Wei, Xiao Xu
Journal: Cellular and Molecular Immunology (2024)
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins
Authors: Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, Michelle Lazenby, Caroline Alvares, Matthias Schmidt, Walburgis Brenner, Sara Najafi, Ina Oehme, Christoph Hieber, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver H Krämer
Journal: Leukemia (2024)
Publisher Correction: Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial
Authors: Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, Ine Moors, Fritz Offner, Anja Velghe, Nele Van Den Noortgate, Pieter Depuydt, Patrick Druwé, Dimitri Hemelsoet, Alfred Meurs, Jiska Malotaux, Wim Van Biesen, Francis Verbeke, Eric Derom, Dieter Stevens, Michel De Pauw, Fiona Tromp, Hans Van Vlierberghe, Eduard Callebout, Katrijn Goethals, An Lievrouw, Limin Liu, Frank Manesse, Stijn Vanheule, Ruth Piers
Journal: Intensive Care Medicine (2024)
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Authors: Andrew J Innes, Chloe Hayden, Victoria Orovboni, Simone Claudiani, Fiona Fernando, Afzal Khan, David Rees, Jennifer Byrne, Paolo Gallipoli, Sebastian Francis, Mhairi Copland, Gillian Horne, Manoj Raghavan, Claire Arnold, Angela Collins, Tanya Cranfield, Nicholas Cunningham, Akila Danga, Peter Forsyth, Rebecca Frewin, Paula Garland, Guy Hannah, Daniele Avenoso, Sandra Hassan, Brian J P Huntly, Jissan Husain, Sudhakaran Makkuni, Kate Rothwell, Jamshid Khorashad, Jane F Apperley, Dragana Milojkovic
Journal: Leukemia (2024)
Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)
Authors: Sebastian Rehberg, Sandra Frank, Vladimír Černý, Radek Cihlář, Rainer Borgstedt, Gianni Biancofiore, Fabio Guarracino, Andreas Schober, Helmut Trimmel, Thomas Pernerstorfer, Christian Siebers, Pavel Dostál, Andrea Morelli, Michael Joannidis, Ingrid Pretsch, Christian Fuchs, Tim Rahmel, Matej Podbregar, Éva Duliczki, Kadri Tamme, Martin Unger, Jan Sus, Christoph Klade, Kurt Krejcy, Nairi Kirchbaumer-Baroian, Günther Krumpl, František Duška
Journal: Intensive Care Medicine (2024)
Current status and research directions in acute myeloid leukemia
Authors: Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J Short, Musa Yilmaz, Farhad Ravandi
Journal: Blood Cancer Journal (2024)